AstraZeneca's highly touted Truqap flunks another phase 3 trial
AstraZeneca has come up short in another phase 3 trial of AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment.
AstraZeneca has come up short in another phase 3 trial of AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment.
